| 375 | Humans |
| 198 | Pandemics |
| 192 | Betacoronavirus |
| 167 | Coronavirus Infections (epidemiology) |
| 162 | Pneumonia, Viral (epidemiology) |
| 116 | Coronavirus Infections (transmission) |
| 111 | Pneumonia, Viral (transmission) |
| 106 | Coronavirus Infections (diagnosis) |
| 92 | Pneumonia, Viral (diagnosis) |
| 84 | Coronavirus Infections (virology) |
| 81 | Animals |
| 79 | Pneumonia, Viral (virology) |
| 76 | Disease Outbreaks |
| 75 | Coronavirus Infections (prevention & control) |
| 67 | China |
| 67 | Betacoronavirus (genetics) |
| 62 | Pneumonia, Viral (prevention & control) |
| 62 | Female |
| 60 | Male |
| 57 | China (epidemiology) |
| 56 | Coronavirus Infections (drug therapy) |
| 52 | Pneumonia, Viral |
| 52 | Betacoronavirus (isolation & purification) |
| 50 | Betacoronavirus (pathogenicity) |
| 47 | SARS Virus |
| 47 | Pandemics (prevention & control) |
| 46 | Adult |
| 45 | Middle Aged |
| 45 | Coronavirus Infections |
| 44 | Clinical Laboratory Techniques |
| 41 | Coronavirus |
| 40 | Coronavirus Infections (therapy) |
| 37 | Pneumonia, Viral (therapy) |
| 34 | Pneumonia, Viral (drug therapy) |
| 33 | Pneumonia, Viral (complications) |
| 33 | Aged |
| 32 | Travel |
| 32 | Coronavirus Infections (complications) |
| 31 | Phylogeny |
| 27 | Public Health |
| 27 | Child |
| 26 | Betacoronavirus (immunology) |
| 25 | Betacoronavirus (physiology) |
| 24 | Severe Acute Respiratory Syndrome (virology) |
| 24 | Genome, Viral |
| 23 | Young Adult |
| 23 | Severe Acute Respiratory Syndrome (epidemiology) |
| 22 | Coronavirus Infections (immunology) |
| 21 | Adolescent |
| 20 | Antiviral Agents (therapeutic use) |
| 19 | Pneumonia, Viral (immunology) |
| 19 | Coronavirus (isolation & purification) |
| 18 | Risk Factors |
| 18 | Chiroptera (virology) |
| 18 | Betacoronavirus (drug effects) |
| 18 | Aged, 80 and over |
| 17 | SARS Virus (pathogenicity) |
| 17 | Retrospective Studies |
| 17 | Global Health |
| 17 | Coronavirus Infections (mortality) |
| 17 | Child, Preschool |
| 16 | Pneumonia, Viral (mortality) |
| 16 | Peptidyl-Dipeptidase A (metabolism) |
| 16 | Contact Tracing |
| 15 | Spike Glycoprotein, Coronavirus (chemistry) |
| 15 | Coronavirus (genetics) |
| 14 | Tomography, X-Ray Computed |
| 14 | Severe Acute Respiratory Syndrome |
| 14 | SARS Virus (genetics) |
| 14 | Quarantine |
| 14 | Infant |
| 14 | Disease Outbreaks (prevention & control) |
| 14 | Antiviral Agents (pharmacology) |
| 13 | World Health Organization |
| 13 | Time Factors |
| 13 | Middle East Respiratory Syndrome Coronavirus |
| 13 | Fever (etiology) |
| 13 | Betacoronavirus (chemistry) |
| 12 | Zoonoses |
| 12 | Receptors, Virus (metabolism) |
| 12 | Pneumonia, Viral (physiopathology) |
| 12 | Coronavirus Infections (physiopathology) |
| 12 | Betacoronavirus (classification) |
| 12 | Amino Acid Sequence |
| 11 | Zoonoses (virology) |
| 11 | Spike Glycoprotein, Coronavirus (genetics) |
| 11 | SARS Virus (immunology) |
| 11 | Population Surveillance |
| 11 | Pneumonia, Viral (diagnostic imaging) |
| 11 | Infection Control (methods) |
| 11 | Epidemics |
| 11 | Cough (etiology) |
| 11 | Coronavirus Infections (diagnostic imaging) |
| 11 | Cell Line |
| 10 | Virus Internalization |
| 10 | Spike Glycoprotein, Coronavirus (immunology) |
| 10 | Severe Acute Respiratory Syndrome (diagnosis) |
| 10 | Reverse Transcriptase Polymerase Chain Reaction |
| 10 | Radiography, Thoracic |
| 10 | Pneumonia, Viral (pathology) |
| 10 | Models, Molecular |
| 10 | Infant, Newborn |
| 10 | Disease Reservoirs (virology) |
| 10 | Coronavirus Infections (pathology) |
| 10 | COVID-19 |
| 9 | Viral Vaccines |
| 9 | Severe Acute Respiratory Syndrome (transmission) |
| 9 | Severe Acute Respiratory Syndrome (immunology) |
| 9 | Real-Time Polymerase Chain Reaction |
| 9 | Protein Binding |
| 9 | Pregnancy |
| 9 | Middle East Respiratory Syndrome Coronavirus (pathogenicity) |
| 9 | Medicine, Chinese Traditional |
| 9 | Italy (epidemiology) |
| 9 | Infection Control |
| 9 | Clinical Trials as Topic |
| 9 | Betacoronavirus (metabolism) |
| 9 | Antibodies, Viral (immunology) |
| 8 | Zoonoses (epidemiology) |
| 8 | Spike Glycoprotein, Coronavirus (metabolism) |
| 8 | Sequence Alignment |
| 8 | SARS-CoV-2 |
| 8 | RNA, Viral (genetics) |
| 8 | Protein Conformation |
| 8 | Practice Guidelines as Topic |
| 8 | Patient Isolation |
| 8 | Mice |
| 8 | Italy |
| 8 | Health Personnel |
| 8 | Feces (virology) |
| 8 | Civil Defense |
| 8 | Chlorocebus aethiops |
| 8 | Chiroptera |
| 8 | Basic Reproduction Number |
| 8 | Antiviral Agents (chemistry) |
| 7 | Severity of Illness Index |
| 7 | Sensitivity and Specificity |
| 7 | Protein Structure, Tertiary |
| 7 | Protein Domains |
| 7 | Models, Theoretical |
| 7 | Lung (diagnostic imaging) |
| 7 | Incidence |
| 7 | Immunization, Passive |
| 7 | Communicable Diseases, Emerging (virology) |
| 7 | Australia (epidemiology) |
| 7 | Asymptomatic Diseases |
| 7 | Antibodies, Viral (blood) |
| 7 | Alanine (analogs & derivatives) |
| 7 | Age Factors |
| 6 | Virus Shedding |
| 6 | Virus Replication |
| 6 | Viral Vaccines (immunology) |
| 6 | Viral Proteins (chemistry) |
| 6 | Viral Load |
| 6 | Vero Cells |
| 6 | United States (epidemiology) |
| 6 | Spike Glycoprotein, Coronavirus |
| 6 | SARS Virus (physiology) |
| 6 | SARS Virus (chemistry) |
| 6 | Middle East Respiratory Syndrome Coronavirus (genetics) |
| 6 | Health Knowledge, Attitudes, Practice |
| 6 | Disease Progression |
| 6 | Coronavirus (classification) |
| 6 | Computational Biology |
| 6 | Communicable Diseases, Emerging |
| 6 | Communicable Diseases, Emerging (epidemiology) |
| 6 | Adenosine Monophosphate (analogs & derivatives) |
| 5 | Structure-Activity Relationship |
| 5 | Severe Acute Respiratory Syndrome (prevention & control) |
| 5 | Risk Assessment |
| 5 | Republic of Korea |
| 5 | RNA, Viral (analysis) |
| 5 | Protein Multimerization |
| 5 | Prognosis |
| 5 | Pneumonia, Viral (metabolism) |
| 5 | Pneumonia, Viral (genetics) |
| 5 | Pneumonia, Viral (blood) |
| 5 | Peptidyl-Dipeptidase A |
| 5 | Peptidyl-Dipeptidase A (genetics) |
| 5 | Nasopharynx (virology) |
| 5 | Mortality |
| 5 | Middle East Respiratory Syndrome Coronavirus (drug effects) |
| 5 | Lung (pathology) |
| 5 | Internationality |
| 5 | Information Dissemination |
| 5 | Influenza A Virus, H1N1 Subtype |
| 5 | Host-Pathogen Interactions |
| 5 | Hospitalization |
| 5 | Genome, Viral (genetics) |
| 5 | Epidemiological Monitoring |
| 5 | Dyspnea (etiology) |
| 5 | Drug Discovery |
| 5 | Drug Design |
| 5 | Dose-Response Relationship, Drug |
| 5 | Disease Reservoirs (veterinary) |
| 5 | Coronavirus Infections (metabolism) |
| 5 | Coronavirus Infections (genetics) |
| 5 | Coronavirus Infections (blood) |
| 5 | Coronavirus (immunology) |
| 5 | Computer Simulation |
| 5 | Comorbidity |
| 5 | Communicable Disease Control (methods) |
| 5 | Cluster Analysis |
| 5 | Binding Sites |
| 4 | Zoonoses (transmission) |
| 4 | Virus Replication (drug effects) |
| 4 | Virus Attachment |
| 4 | Viral Proteins (metabolism) |
| 4 | Viral Proteins (genetics) |
| 4 | Viral Envelope Proteins (immunology) |
| 4 | Vaccination |
| 4 | United Kingdom (epidemiology) |
| 4 | Travel-Related Illness |
| 4 | Severe Acute Respiratory Syndrome (therapy) |
| 4 | Severe Acute Respiratory Syndrome (pathology) |
| 4 | Severe Acute Respiratory Syndrome (drug therapy) |
| 4 | Sequence Analysis, Protein |
| 4 | Sentinel Surveillance |
| 4 | SARS Virus (metabolism) |
| 4 | SARS Virus (drug effects) |
| 4 | SARS Virus (classification) |
| 4 | Republic of Korea (epidemiology) |
| 4 | Receptors, Virus (genetics) |
| 4 | Receptors, Virus (chemistry) |
| 4 | RNA, Viral (isolation & purification) |
| 4 | Polymerase Chain Reaction |
| 4 | Pneumonia, Viral (veterinary) |
| 4 | Pharynx (virology) |
| 4 | Pandemics (statistics & numerical data) |
| 4 | Neutralization Tests |
| 4 | Neoplasms |
| 4 | Molecular Structure |
| 4 | Molecular Docking Simulation |
| 4 | Middle East Respiratory Syndrome Coronavirus (physiology) |
| 4 | Microbial Sensitivity Tests |
| 4 | Mass Screening |
| 4 | Influenza, Human (diagnosis) |
| 4 | Infectious Disease Transmission, Patient-to-Professional (prevention & control) |
| 4 | Infectious Disease Incubation Period |
| 4 | Germany |
| 4 | Fever |
| 4 | Evolution, Molecular |
| 4 | Europe (epidemiology) |
| 4 | Disease Transmission, Infectious |
| 4 | Disease Transmission, Infectious (prevention & control) |
| 4 | Disease Reservoirs |
| 4 | Disease Models, Animal |
| 4 | Critical Illness |
| 4 | Coronavirus Infections (veterinary) |
| 4 | Cohort Studies |
| 4 | Clinical Laboratory Techniques (methods) |
| 4 | Biological Evolution |
| 4 | Betacoronavirus (growth & development) |
| 4 | Asymptomatic Infections |
| 4 | Antibodies, Neutralizing (therapeutic use) |
| 4 | Alanine (pharmacology) |
| 4 | Air Travel |
| 3 | coronavirus |
| 3 | Viral Envelope Proteins (metabolism) |
| 3 | Viral Envelope Proteins (chemistry) |
| 3 | United States |
| 3 | Uncertainty |
| 3 | Trypsin (metabolism) |
| 3 | Surveys and Questionnaires |
| 3 | Sputum (virology) |
| 3 | Spike Glycoprotein, Coronavirus (ultrastructure) |
| 3 | Spike Glycoprotein, Coronavirus (antagonists & inhibitors) |
| 3 | Singapore (epidemiology) |
| 3 | Severe acute respiratory syndrome |
| 3 | Risk |
| 3 | Respiratory Insufficiency (etiology) |
| 3 | Respiration, Artificial |
| 3 | Reproducibility of Results |
| 3 | Real-Time Polymerase Chain Reaction (methods) |
| 3 | Public Health Surveillance |
| 3 | Public Health Practice |
| 3 | Protein Structure, Secondary |
| 3 | Pneumonia, Viral (psychology) |
| 3 | Pneumonia, Viral (etiology) |
| 3 | Pharyngitis (etiology) |
| 3 | Personal Protective Equipment |
| 3 | Personal Protective Equipment (supply & distribution) |
| 3 | Peptidyl-Dipeptidase A (physiology) |
| 3 | Peptidyl-Dipeptidase A (chemistry) |
| 3 | Oropharynx (virology) |
| 3 | Nucleocapsid Proteins (chemistry) |
| 3 | Mutation |
| 3 | Mortality (trends) |
| 3 | Mental Health |
| 3 | Mass Screening (methods) |
| 3 | Lung (virology) |
| 3 | Interleukin-6 (immunology) |
| 3 | Interleukin-6 (antagonists & inhibitors) |
| 3 | Intensive Care Units, Neonatal |
| 3 | Influenza, Human (epidemiology) |
| 3 | Infectious Disease Transmission, Vertical |
| 3 | Immunologic Factors (therapeutic use) |
| 3 | Immunoglobulin M (blood) |
| 3 | Immunoglobulin G (immunology) |
| 3 | Immunoglobulin G (blood) |
| 3 | Immunization |
| 3 | HEK293 Cells |
| 3 | Genetic Variation |
| 3 | Gene Expression Profiling |
| 3 | France (epidemiology) |
| 3 | Forecasting |
| 3 | Epitopes, T-Lymphocyte (immunology) |
| 3 | Epitopes, B-Lymphocyte (immunology) |
| 3 | Epitopes (immunology) |
| 3 | Environmental Microbiology |
| 3 | Endocytosis |
| 3 | Emergency Service, Hospital |
| 3 | Emergencies |
| 3 | Drugs, Chinese Herbal (therapeutic use) |
| 3 | Drug Repositioning |
| 3 | Drug Evaluation, Preclinical |
| 3 | Dipeptidyl Peptidase 4 (metabolism) |
| 3 | Diarrhea (virology) |
| 3 | Diagnosis, Differential |
| 3 | Cytokines (metabolism) |
| 3 | Cytokines (immunology) |
| 3 | Crystallography, X-Ray |
| 3 | Cryoelectron Microscopy |
| 3 | Cross Reactions |
| 3 | Critical Care |
| 3 | Cough |
| 3 | Coronavirus Infections (psychology) |
| 3 | Community-Acquired Infections (transmission) |
| 3 | Communicable Diseases, Emerging (transmission) |
| 3 | Cardiovascular Diseases (virology) |
| 3 | Bronchoalveolar Lavage Fluid (virology) |
| 3 | Biomedical Research |
| 3 | Betacoronavirus (ultrastructure) |
| 3 | Bayes Theorem |
| 3 | Autopsy |
| 3 | Antimalarials (therapeutic use) |
| 3 | Antibodies, Viral (therapeutic use) |
| 3 | Antibodies, Neutralizing (immunology) |
| 3 | Antibodies, Monoclonal, Humanized (therapeutic use) |
| 3 | Antibodies, Monoclonal (therapeutic use) |
| 3 | Antibodies, Monoclonal (immunology) |
| 3 | Anti-Inflammatory Agents (therapeutic use) |
| 3 | Alphacoronavirus (genetics) |
| 3 | Alanine (therapeutic use) |
| 3 | Alanine (chemistry) |
| 3 | Age Distribution |
| 3 | Adenosine Monophosphate (therapeutic use) |
| 3 | Adenosine Monophosphate (pharmacology) |
| 3 | Adaptive Immunity |
| 2 | outbreak |
| 2 | Zoonoses (prevention & control) |
| 2 | Workflow |
| 2 | Whole Genome Sequencing |
| 2 | Whole Genome Sequencing (methods) |
| 2 | Washington (epidemiology) |
| 2 | Virus Diseases (virology) |
| 2 | Virus Diseases (transmission) |
| 2 | Virus Diseases (drug therapy) |
| 2 | Virus Attachment (drug effects) |
| 2 | Virulence |
| 2 | Viral Vaccines (therapeutic use) |
| 2 | Viral Proteins |
| 2 | Viral Proteins (antagonists & inhibitors) |
| 2 | Viral Proteins (analysis) |
| 2 | Viral Nonstructural Proteins (genetics) |
| 2 | Viral Envelope Proteins |
| 2 | Viral Envelope Proteins (genetics) |
| 2 | Viral Envelope Proteins (analysis) |
| 2 | Vaccines, Synthetic |
| 2 | Two-Hybrid System Techniques |
| 2 | Treatment Outcome |
| 2 | Transcriptome |
| 2 | Testis (virology) |
| 2 | Testis (metabolism) |
| 2 | Testis (cytology) |
| 2 | T-Lymphocytes (immunology) |
| 2 | Surveillance |
| 2 | Spouses |
| 2 | Societies, Medical |
| 2 | Social Conditions |
| 2 | Singapore |
| 2 | Sex Factors |
| 2 | Severe Acute Respiratory Syndrome (history) |
| 2 | Severe Acute Respiratory Syndrome (etiology) |
| 2 | Serologic Tests |
| 2 | Serologic Tests (methods) |
| 2 | Seroepidemiologic Studies |
| 2 | Serine Endopeptidases (metabolism) |
| 2 | Sequence Homology, Amino Acid |
| 2 | SARS-CoV |
| 2 | Respiratory Tract Infections (diagnosis) |
| 2 | Respiratory System (virology) |
| 2 | Respiratory Protective Devices |
| 2 | Respiratory Insufficiency |
| 2 | Respiratory Distress Syndrome, Adult (therapy) |
| 2 | Respiration, Artificial (methods) |
| 2 | Recombination, Genetic |
| 2 | Recombinant Proteins (therapeutic use) |
| 2 | Receptors, Virus (ultrastructure) |
| 2 | Randomized Controlled Trials as Topic |
| 2 | RNA |
| 2 | RNA Replicase (metabolism) |
| 2 | RNA Replicase (genetics) |
| 2 | RNA Replicase (chemistry) |
| 2 | RNA Replicase (antagonists & inhibitors) |
| 2 | Public Policy |
| 2 | Proteome |
| 2 | Protein Interaction Mapping |
| 2 | Protein Interaction Domains and Motifs |
| 2 | Protein Conformation, alpha-Helical |
| 2 | Protease Inhibitors (therapeutic use) |
| 2 | Protease Inhibitors (pharmacology) |
| 2 | Prevalence |
| 2 | Pregnancy Outcome |
| 2 | Pregnancy Complications, Infectious (prevention & control) |
| 2 | Politics |
| 2 | Point Mutation |
| 2 | Pneumonia |
| 2 | Pneumonia, Viral (enzymology) |
| 2 | Pneumonia, Viral (economics) |
| 2 | Plasma |
| 2 | Personnel, Hospital (statistics & numerical data) |
| 2 | Perinatal Care |
| 2 | Patient Care Team |
| 2 | Pandemics (economics) |
| 2 | Nucleocapsid Proteins (metabolism) |
| 2 | Nucleocapsid Proteins (genetics) |
| 2 | Neuraminidase (metabolism) |
| 2 | Mouth (virology) |
| 2 | Molecular Targeted Therapy |
| 2 | Molecular Dynamics Simulation |
| 2 | Molecular Diagnostic Techniques (methods) |
| 2 | Models, Animal |
| 2 | Middle East Respiratory Syndrome Coronavirus (immunology) |
| 2 | Microscopy, Electron, Transmission |
| 2 | Microbial Viability |
| 2 | Metal Nanoparticles (chemistry) |
| 2 | Membrane Glycoproteins (metabolism) |
| 2 | Membrane Glycoproteins (immunology) |
| 2 | Membrane Glycoproteins (chemistry) |
| 2 | Membrane Fusion |
| 2 | Medicine, Chinese Traditional (methods) |
| 2 | Medical Records |
| 2 | Medical History Taking |
| 2 | Masks (supply & distribution) |
| 2 | Lymphopenia |
| 2 | Lymphopenia (etiology) |
| 2 | Internet |
| 2 | Interferon |
| 2 | Influenza, Human (transmission) |
| 2 | Infectious Disease Transmission, Patient-to-Professional |
| 2 | Immunosuppressive Agents (therapeutic use) |
| 2 | Immunoglobulin A (blood) |
| 2 | Immunocompromised Host |
| 2 | Immunity, Innate |
| 2 | Immune Evasion |
| 2 | Hypoxia (etiology) |
| 2 | Hypertension |
| 2 | Hypertension (complications) |
| 2 | Human Activities |
| 2 | Hot Temperature |
| 2 | Hospitals |
| 2 | History, 19th Century |
| 2 | High-Throughput Nucleotide Sequencing (methods) |
| 2 | Heart Arrest (etiology) |
| 2 | Health Planning |
| 2 | Health Facilities |
| 2 | Health Communication |
| 2 | HIV (drug effects) |
| 2 | Guidelines as Topic |
| 2 | Gold (chemistry) |
| 2 | Global Health (trends) |
| 2 | Global Health (statistics & numerical data) |
| 2 | Genomics |
| 2 | Genetic Engineering |
| 2 | France |
| 2 | Flow Cytometry |
| 2 | Fever (virology) |
| 2 | Fatigue (etiology) |
| 2 | Family Health |
| 2 | Evidence-Based Medicine |
| 2 | Evaluation Studies as Topic |
| 2 | Eutheria (virology) |
| 2 | European Union |
| 2 | Europe |
| 2 | Epitopes, T-Lymphocyte (genetics) |
| 2 | Epitopes, B-Lymphocyte (genetics) |
| 2 | Epitope Mapping |
| 2 | Epidemiology |
| 2 | Epidemics (prevention & control) |
| 2 | Enzyme-Linked Immunosorbent Assay |
| 2 | Early Diagnosis |
| 2 | Drug Resistance, Viral |
| 2 | Drug Development |
| 2 | Disease Susceptibility |
| 2 | Disease Outbreaks (statistics & numerical data) |
| 2 | Disease Notification (statistics & numerical data) |
| 2 | Disaster Planning |
| 2 | Diarrhea (etiology) |
| 2 | Dental Care (standards) |
